Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

NCT05430399 | Recruiting Phase 3

• 1 other identifier: SYSU-2022-UCAN
• Study Type: interventional
• Target: 349
• Locations: 1 country
• Sites: 2

Brief Summary

It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.

Conditions

Breast Neoplasms; Locally Advanced or Metastatic Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Progression Free Survival (PFS)

  Time from randomization to progression or death (whichever occurred first)

  up to 60 months

Secondary Outcomes (5)

• Objective response rate (ORR)

  up to 60 months

• Time to response (TTR)

  up to 60 months

• Duration of response (DOR)

  up to 60 months

• Overall survival (OS)

  up to 60 months

• Patient-reported health-related quality of life (QoL): FACT-B total score

  up to 60 months

Study Arms (2)

Arm A

EXPERIMENTAL

utidelone

Drug: utidelone

Arm B

ACTIVE COMPARATOR

docetaxel

Drug: docetaxel

Interventions

utidelone DRUG

Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Arm A

docetaxel DRUG

Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Arm B

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed the informed consent form;
• Women aged ≥ 18 years;
• Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer;
• The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative;
• Eastern Cooperative Oncology Group (ECOG) score \[0-1\] points;
• Patients must have metastatic disease that is evaluable on imaging: including at least one measurable lesion (assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)); or only non-measurable disease as defined by RECIST 1.1 , especially in patients with bone metastases only, while the disease could be documented/assessed by bone scan, PET or MRI;
• Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomization;
• No previous chemotherapy for advanced breast cancer ;
• For HR+ breast cancer patients shall meet one of the two criteria below: a) radiographically confirmed recurrence or progression within 2 years of adjuvant endocrine therapy; b) received at least one line of endocrine therapy in the recurrence or metastasis stage;
• Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia were allowed ;
• Patients with asymptomatic CNS metastases may be enrolled, if:
• Intracranial lesions are evaluable and eligible for systemic therapy only in the absence of extracranial evaluable lesions, or
• Patients with stable intracranial lesions after local treatment while there are extracranial evaluable lesions ;
• Adequate hematological, hepatic and renal function;
• Women of childbearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment;

You may not qualify if:

• HER-2 positive (IHC 3+, or FISH positive);
• Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;
• Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy;
• Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first dose of treatment, or anticipating for a major surgical procedure during the study;
• Experienced grade ≥ 3 nervous system-related adverse events after treatment with anti-microtubule drugs;
• Symptomatic central nervous system metastases;
• Pregnant or lactating women;
• Known or suspected hypersensitivity to any of the study drugs or excipients;
• Any other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that precludes study treatment implementation or follow-up ;
• Any other condition that the investigator considers inappropriate to participate in this trial .
• Use of corticosteroids is prohibited.

Sponsors & Collaborators

• Sun Yat-sen University: lead
• Beijing Biostar Pharmaceuticals Co., Ltd.: collaborator
• Hunan Cancer Hospital: collaborator

Study Sites (2)

Shusen Wang

Guangzhou, Gangdong, China

RECRUITING

Hunan Cancer Hospital

Hunan, Hunan, 410000, China

NOT YET RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Docetaxel

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Central Study Contacts

shusen wang, MD

CONTACT

+86-020-87342693; wangshs@sysucc.org.cn

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician

Study Record Dates

• First Submitted: June 2, 2022
• First Posted: June 24, 2022
• Study Start: June 21, 2022
• Primary Completion: June 1, 2025
• Study Completion (Estimated): June 1, 2027
• Last Updated: July 13, 2023

Record last verified: 2023-07

Locations

CN (2)